February 2, 2016—Two drug companies under congressional investigation for price gouging used tactics that “are not limited to a few ‘bad apples,’ but are prominent throughout the industry,” the ranking Democrat on the House Oversight committee said today upon releasing summaries of more than 300,000 pages of documents from the companies in advance of a Feb. 4 hearing.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)